Results 111 to 120 of about 5,180,843 (313)
, 2019 Figure S5. Co-localization of CD3 and FoxP3 in the human AD brain. Immunofluorescence in representative samples for both molecules was detected in immune cells in the hippocampus of AD patients, whereas it was absent in the brain of healthy individuals (merge column; DAPIâ =â nuclear staining).
Di Benedetto, Giulia +8 more
openaire +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak +4 more
wiley +1 more source
PLoS ONE, 2019 Gene-environment (GxE) interaction is one potential explanation for the missing heritability problem. A popular approach to genome-wide environment interaction studies (GWEIS) is based on regression models involving interactions between genetic variants ...
Masao Ueki +3 more
doaj +1 more source
Additional file 1: of A phase III randomized trial of gantenerumab in prodromal Alzheimerâ s disease
, 2017 List of institutional review boards and independent ethics committees. (DOCX 20 kb)
Ostrowitzki, Susanne +16 more
openaire +1 more source
Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Plasma tau phosphorylated at threonine 217 (p‐tau217) measured with fully automated platforms has shown high accuracy for Alzheimer's disease (AD) diagnosis, but real‐world multicenter data remain limited. We aimed to validate the diagnostic performance of p‐tau217 for identifying AD pathology in a real‐world multicenter cohort ...
Miquel Massons +33 more
wiley +1 more source
, 2019 Figure S7. Negative controls for Fig. 8, panel b (phosphorylated Tau protein expression). Negative controls are reported in all panels marked with acronyms of secondary antibodies labeled with, Alexa Fluor 488. (PDF 491 kb)
Di Benedetto, Giulia +8 more
openaire +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw +5 more
wiley +1 more source
Final Report: 2007 Alzheimer's Disease Task Force, January 2008 [PDF]
, 2008 Following an overview of the history of the task force and background information on Alzheimer’s disease, the report is divided into four sections. These sections correspond to the delineation of four subcommittees into which task force members were ...
core
Associations of stable psychological traits with multi-omic subtypes of Alzheimer’s dementia
Translational PsychiatryPsychological traits reflecting neuroticism, depressive symptoms, loneliness, and purpose in life are risk factors of AD dementia; however, the underlying biological mechanisms remain largely unknown.
Andrea R. Zammit +11 more
doaj +1 more source
Variation in TMEM106B in chronic traumatic encephalopathy
Acta Neuropathologica Communications, 2018 The genetic basis of chronic traumatic encephalopathy (CTE) is poorly understood. Variation in transmembrane protein 106B (TMEM106B) has been associated with enhanced neuroinflammation during aging and with TDP-43-related neurodegenerative disease, and ...
Jonathan D. Cherry +26 more
doaj +1 more source